Cardiol Therapeutics (CRDL) Gains from Investment Securities (2022 - 2024)
Cardiol Therapeutics (CRDL) posted Gains from Investment Securities of -$109437.8 for Q2 2024, up 69.97% on a QoQ basis from -$364449.6 in Q1 2024, and up 82.63% year-over-year from -$59921.8 in Q3 2023.
Cardiol Therapeutics (CRDL) Gains from Investment Securities (2022 - 2024) Analysis & Trends
Cardiol Therapeutics' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at -$109437.8 for Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn |
| 10 | Cardiol Therapeutics | 127.60 Mn | 127.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -109,437.85 |
| Jun 30, 2024 | -109,437.85 |
| Mar 31, 2024 | -364,449.57 |
| Mar 31, 2024 | -364,449.57 |
| Sep 30, 2023 | 722,212.12 |
| Sep 30, 2023 | 722,212.12 |
| Jun 30, 2023 | -630,201.35 |
| Jun 30, 2023 | -630,201.35 |
| Mar 31, 2023 | -2,041.56 |
| Mar 31, 2023 | -2,041.56 |
| Sep 30, 2022 | 2.46 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | -1.10 Mn |
| Mar 31, 2022 | -1.10 Mn |